Thank you
for your subscription!
Check out some of our recent updates on the right.
DiaCarta’s Multivariant COVID-19 Test Accurately Detects the Omicron Variant
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.
Early Cancer Detection Will Save More Lives
linkedinfacebooktwitterCancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone....
Assay Detects Precancerous Colorectal Cancer Lesions & Mutations
linkedinfacebooktwitterWritten by Chris Wolskiat Clinical Lab Products Read the article on Clinical Lab Products
DiaCarta and the Scientific World Mourns the Passing of CSO, Michael J. Powell, Ph.D.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel virology and oncology tests, mourns the passing of Michael “Mike” J. Powell, Ph.D., Chief Scientific Officer of DiaCarta.
SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say
linkedinfacebooktwitterWritten by Madeleine Johnsonat GenomeWeb Read the article on genomeweb Download the article